Advanced

Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial

Davies, SJ; Woodrow, G; Donovan, K; Plum, J; Williams, P; Johansson, AC; Bosselmann, HP; Heimburger, O; Simonsen, Ole LU and Davenport, A, et al. (2003) In Journal of the American Society of Nephrology 14(9). p.2338-2344
Abstract
Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output <750 ml/d, high solute transport, and either treated hypertension or untreated BP >140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in... (More)
Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output <750 ml/d, high solute transport, and either treated hypertension or untreated BP >140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in total body water were observed, largely explained by reduced extracellular fluid volume in those receiving icodextrin, who also achieved better ultrafiltration and total sodium losses at 3 mo (P < 0.05) and had better maintenance of urine volume at 6 mo (P = 0.039). In patients fulfilling the study's inclusion criteria, the use of icodextrin, when compared with 2.27% glucose, in the long exchange improves fluid removal and status in peritoneal dialysis. This effect is apparent within I mo of commencement and was sustained for 6 mo without harmful effects on residual renal function. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of the American Society of Nephrology
volume
14
issue
9
pages
2338 - 2344
publisher
American Society of Nephrology
external identifiers
  • wos:000185025500015
  • pmid:12937311
  • scopus:10744222476
ISSN
1046-6673
DOI
10.1097/01.ASN.0000083904.12234.27
language
English
LU publication?
yes
id
4055c5e0-3b00-419c-b439-82b9747ff601 (old id 302199)
alternative location
http://jasn.asnjournals.org/cgi/content/abstract/14/9/2338
date added to LUP
2007-08-29 10:34:12
date last changed
2018-08-05 04:08:08
@article{4055c5e0-3b00-419c-b439-82b9747ff601,
  abstract     = {Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output &lt;750 ml/d, high solute transport, and either treated hypertension or untreated BP &gt;140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in total body water were observed, largely explained by reduced extracellular fluid volume in those receiving icodextrin, who also achieved better ultrafiltration and total sodium losses at 3 mo (P &lt; 0.05) and had better maintenance of urine volume at 6 mo (P = 0.039). In patients fulfilling the study's inclusion criteria, the use of icodextrin, when compared with 2.27% glucose, in the long exchange improves fluid removal and status in peritoneal dialysis. This effect is apparent within I mo of commencement and was sustained for 6 mo without harmful effects on residual renal function.},
  author       = {Davies, SJ and Woodrow, G and Donovan, K and Plum, J and Williams, P and Johansson, AC and Bosselmann, HP and Heimburger, O and Simonsen, Ole and Davenport, A and Tranaeus, A and Divino, JC},
  issn         = {1046-6673},
  language     = {eng},
  number       = {9},
  pages        = {2338--2344},
  publisher    = {American Society of Nephrology},
  series       = {Journal of the American Society of Nephrology},
  title        = {Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial},
  url          = {http://dx.doi.org/10.1097/01.ASN.0000083904.12234.27},
  volume       = {14},
  year         = {2003},
}